Antidepressants Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Selective Serotonin Reuptake Inhibitors, Serotonin & Norepinephrine Reuptake Inhibitors, Atypical Antidepressants, Tricyclic Antidepressants), By Disorder (Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy), and Regional Forecast, 2020-2027

Last Updated: February 17, 2025 | Format: PDF | Report ID: FBI105017

Table of Content

Introduction
1. Market Scope
2. Market Segmentation
3. Market Methodology
4. Definitions and Assumptions
Executive Summary
Market Dynamics
1. Market Drivers
2. Market Restraints
3. Market Opportunities
Key Insights
1. Prevalence of Anxiety & Depression –Key Regions/Country
2. New Product Launch
3. Pipeline Analysis
4. Impact of COVID-19 on the Antidepressants Market
5. Key Industry Developments - Mergers, Acquisitions, and Partnerships
Global Antidepressants Market Analysis, Insights and Forecast, 2016-2027
1. Key Findings / Summary
2. Market Analysis, Insights and Forecast – By Drug Class
  1. Selective Serotonin Reuptake Inhibitors (SSRIs)
  2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)
  3. Atypical Antidepressants
  4. Tricyclic Antidepressants (TCAs)
  5. Monoamine Oxidase Inhibitors (MAOIs)
  6. Others
3. Market Analysis, Insights and Forecast – By Disorder
  1. Major Depressive Disorder
  2. Obsessive Compulsive Disorder
  3. Generalized Anxiety Disorder
  4. Panic Disorder
  5. Others
4. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacy
  2. Retail Pharmacy
  3. Online Pharmacy
5. Market Analysis, Insights and Forecast – By Geography
  1. North America
  2. Europe
  3. Asia Pacific
  4. Latin America
  5. Middle East & Africa
North America Antidepressants Market Analysis, Insights and Forecast, 2016-2027
1. Key Findings / Summary
2. Market Analysis, Insights and Forecast – By Drug Class
  1. Selective Serotonin Reuptake Inhibitors (SSRIs)
  2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)
  3. Atypical Antidepressants
  4. Tricyclic Antidepressants (TCAs)
  5. Monoamine Oxidase Inhibitors (MAOIs)
  6. Others
3. Market Analysis, Insights and Forecast – By Disorder
  1. Major Depressive Disorder
  2. Obsessive Compulsive Disorder
  3. Generalized Anxiety Disorder
  4. Panic Disorder
  5. Others
4. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacy
  2. Retail Pharmacy
  3. Online Pharmacy
5. Market Analysis, Insights and Forecast – By Country
  1. U.S.
    1. By Disorder
      1. Major Depressive Disorder
      2. Obsessive Compulsive Disorder
      3. Generalized Anxiety Disorder
      4. Panic Disorder
      5. Others
  2. Canada
    1. By Disorder
      1. Major Depressive Disorder
      2. Obsessive Compulsive Disorder
      3. Generalized Anxiety Disorder
      4. Panic Disorder
      5. Others
Europe Antidepressants Market Analysis, Insights and Forecast, 2016-2027
1. Key Findings / Summary
2. Market Analysis, Insights and Forecast – By Drug Class
  1. Selective Serotonin Reuptake Inhibitors (SSRIs)
  2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)
  3. Atypical Antidepressants
  4. Tricyclic Antidepressants (TCAs)
  5. Monoamine Oxidase Inhibitors (MAOIs)
  6. Others
3. Market Analysis, Insights and Forecast – By Disorder
  1. Major Depressive Disorder
  2. Obsessive Compulsive Disorder
  3. Generalized Anxiety Disorder
  4. Panic Disorder
  5. Others
4. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacy
  2. Retail Pharmacy
  3. Online Pharmacy
5. Market Analysis, Insights and Forecast – By Country/Sub-region
  1. U.K.
    1. By Disorder
      1. Major Depressive Disorder
      2. Obsessive Compulsive Disorder
      3. Generalized Anxiety Disorder
      4. Panic Disorder
      5. Others
  2. Germany
    1. By Disorder
      1. Major Depressive Disorder
      2. Obsessive Compulsive Disorder
      3. Generalized Anxiety Disorder
      4. Panic Disorder
      5. Others
  3. France
    1. By Disorder
      1. Major Depressive Disorder
      2. Obsessive Compulsive Disorder
      3. Generalized Anxiety Disorder
      4. Panic Disorder
      5. Others
  4. Spain
    1. By Disorder
      1. Major Depressive Disorder
      2. Obsessive Compulsive Disorder
      3. Generalized Anxiety Disorder
      4. Panic Disorder
      5. Others
  5. Italy
    1. By Disorder
      1. Major Depressive Disorder
      2. Obsessive Compulsive Disorder
      3. Generalized Anxiety Disorder
      4. Panic Disorder
      5. Others
  6. Scandinavia
    1. By Disorder
      1. Major Depressive Disorder
      2. Obsessive Compulsive Disorder
      3. Generalized Anxiety Disorder
      4. Panic Disorder
      5. Others
  7. Rest of Europe
    1. By Disorder
      1. Major Depressive Disorder
      2. Obsessive Compulsive Disorder
      3. Generalized Anxiety Disorder
      4. Panic Disorder
      5. Others
Asia Pacific Antidepressants Market Analysis, Insights and Forecast, 2016-2027
1. Key Findings / Summary
2. Market Analysis, Insights and Forecast – By Drug Class
  1. Selective Serotonin Reuptake Inhibitors (SSRIs)
  2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)
  3. Atypical Antidepressants
  4. Tricyclic Antidepressants (TCAs)
  5. Monoamine Oxidase Inhibitors (MAOIs)
  6. Others
3. Market Analysis, Insights and Forecast – By Disorder
  1. Major Depressive Disorder
  2. Obsessive Compulsive Disorder
  3. Generalized Anxiety Disorder
  4. Panic Disorder
  5. Others
4. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacy
  2. Retail Pharmacy
  3. Online Pharmacy
5. Market Analysis, Insights and Forecast – By Country/Sub-region
  1. Japan
    1. By Disorder
      1. Major Depressive Disorder
      2. Obsessive Compulsive Disorder
      3. Generalized Anxiety Disorder
      4. Panic Disorder
      5. Others
  2. China
    1. By Disorder
      1. Major Depressive Disorder
      2. Obsessive Compulsive Disorder
      3. Generalized Anxiety Disorder
      4. Panic Disorder
      5. Others
  3. India
    1. By Disorder
      1. Major Depressive Disorder
      2. Obsessive Compulsive Disorder
      3. Generalized Anxiety Disorder
      4. Panic Disorder
      5. Others
  4. Australia
    1. By Disorder
      1. Major Depressive Disorder
      2. Obsessive Compulsive Disorder
      3. Generalized Anxiety Disorder
      4. Panic Disorder
      5. Others
  5. Southeast Asia
    1. By Disorder
      1. Major Depressive Disorder
      2. Obsessive Compulsive Disorder
      3. Generalized Anxiety Disorder
      4. Panic Disorder
  6. Rest of Asia Pacific
    1. By Disorder
      1. Major Depressive Disorder
      2. Obsessive Compulsive Disorder
      3. Generalized Anxiety Disorder
      4. Panic Disorder
      5. Others
Latin America Antidepressants Market Analysis, Insights and Forecast, 2016-2027
1. Key Findings / Summary
2. Market Analysis, Insights and Forecast – By Drug Class
  1. Selective Serotonin Reuptake Inhibitors (SSRIs)
  2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)
  3. Atypical Antidepressants
  4. Tricyclic Antidepressants (TCAs)
  5. Monoamine Oxidase Inhibitors (MAOIs)
  6. Others
3. Market Analysis, Insights and Forecast – By Disorder
  1. Major Depressive Disorder
  2. Obsessive Compulsive Disorder
  3. Generalized Anxiety Disorder
  4. Panic Disorder
  5. Others
4. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacy
  2. Retail Pharmacy
  3. Online Pharmacy
5. Market Analysis, Insights and Forecast – By Country/Sub-region
  1. Brazil
    1. By Disorder
      1. Major Depressive Disorder
      2. Obsessive Compulsive Disorder
      3. Generalized Anxiety Disorder
      4. Panic Disorder
      5. Others
  2. Mexico
    1. By Disorder
      1. Major Depressive Disorder
      2. Obsessive Compulsive Disorder
      3. Generalized Anxiety Disorder
      4. Panic Disorder
      5. Others
  3. Rest of Latin America
    1. By Disorder
      1. Major Depressive Disorder
      2. Obsessive Compulsive Disorder
      3. Generalized Anxiety Disorder
      4. Panic Disorder
      5. Others
Middle East & Africa Antidepressants Market Analysis, Insights and Forecast, 2016-2027
1. Key Findings / Summary
2. Market Analysis, Insights and Forecast – By Drug Class
  1. Selective Serotonin Reuptake Inhibitors (SSRIs)
  2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)
  3. Atypical Antidepressants
  4. Tricyclic Antidepressants (TCAs)
  5. Monoamine Oxidase Inhibitors (MAOIs)
  6. Others
3. Market Analysis, Insights and Forecast – By Disorder
  1. Major Depressive Disorder
  2. Obsessive Compulsive Disorder
  3. Generalized Anxiety Disorder
  4. Panic Disorder
  5. Others
4. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacy
  2. Retail Pharmacy
  3. Online Pharmacy
5. Market Analysis, Insights and Forecast – By Country/Sub-region
  1. GCC
    1. By Disorder
      1. Major Depressive Disorder
      2. Obsessive Compulsive Disorder
      3. Generalized Anxiety Disorder
      4. Panic Disorder
      5. Others
  2. South Africa
    1. By Disorder
      1. Major Depressive Disorder
      2. Obsessive Compulsive Disorder
      3. Generalized Anxiety Disorder
      4. Panic Disorder
      5. Others
  3. Rest of Middle East & Africa
    1. By Disorder
      1. Major Depressive Disorder
      2. Obsessive Compulsive Disorder
      3. Generalized Anxiety Disorder
      4. Panic Disorder
      5. Others
Competitive Analysis
1. Key Industry Developments
2. Global Market Share Analysis (2019)
3. Company Profiles (Overview, Drug Class, SWOT Analysis, Recent Developments, Strategies, Financials (Based on Availability))
  1. H. Lundbeck A/S
    1. Overview,
    2. Drug Class,
    3. SWOT Analysis,
    4. Recent Developments,
    5. Strategies,
    6. Financials (Based on Availability)
  2. GlaxoSmithKline plc
    1. Overview,
    2. Drug Class,
    3. SWOT Analysis,
    4. Recent Developments,
    5. Strategies,
    6. Financials (Based on Availability)
  3. Eli Lilly and Company
    1. Overview,
    2. Drug Class,
    3. SWOT Analysis,
    4. Recent Developments,
    5. Strategies,
    6. Financials (Based on Availability)
  4. Janssen Pharmaceuticals
    1. Overview,
    2. Drug Class,
    3. SWOT Analysis,
    4. Recent Developments,
    5. Strategies,
    6. Financials (Based on Availability)
  5. Pfizer Inc.
    1. Overview,
    2. Drug Class,
    3. SWOT Analysis,
    4. Recent Developments,
    5. Strategies,
    6. Financials (Based on Availability)
  6. Merck & Co. Inc.
    1. Overview,
    2. Drug Class,
    3. SWOT Analysis,
    4. Recent Developments,
    5. Strategies,
    6. Financials (Based on Availability)
  7. AztraZeneca
    1. Overview,
    2. Drug Class,
    3. SWOT Analysis,
    4. Recent Developments,
    5. Strategies,
    6. Financials (Based on Availability)
  8. Bristol-Myers Squibb
    1. Overview,
    2. Drug Class,
    3. SWOT Analysis,
    4. Recent Developments,
    5. Strategies,
    6. Financials (Based on Availability)
  9. Teva Pharmaceutical Industries Ltd.
    1. Overview,
    2. Drug Class,
    3. SWOT Analysis,
    4. Recent Developments,
    5. Strategies,
    6. Financials (Based on Availability)
  10. Other Prominent Players
    1. Overview,
    2. Drug Class,
    3. SWOT Analysis,
    4. Recent Developments,
    5. Strategies,
    6. Financials (Based on Availability)
Strategic Recommendations

Read Less

List of Figures

Figure 1: Global Antidepressants Market Revenue Breakdown (USD billion, %) by Region, 2019 & 2027

Figure 2: Global Antidepressants Market Value Share (%), by Drug Class, 2019 & 2027

Figure 3: Global Antidepressants Market Forecast (USD billion), by Selective Serotonin Reuptake Inhibitors (SSRIs), 2016-2027

Figure 4: Global Antidepressants Market Forecast (USD billion), by Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs), 2016-2027

Figure 5: Global Antidepressants Market Forecast (USD billion), by Atypical Antidepressants, 2016-2027

Figure 6: Global Antidepressants Market Forecast (USD billion), by Tricyclic Antidepressants (TCAs), 2016-2027

Figure 7: Global Antidepressants Market Forecast (USD billion), by Monoamine Oxidase Inhibitors (MAOIs), 2016-2027

Figure 8: Global Antidepressants Market Forecast (USD billion), by Others, 2016-2028

Figure 9: Global Antidepressants Market Value Share (%), by Disorder, 2019 & 2027

Figure 10: Global Antidepressants Market Forecast (USD billion), by Major Depressive Disorder, 2016-2027

Figure 11: Global Antidepressants Market Forecast (USD billion), by Obsessive Compulsive Disorder, 2016-2027

Figure 12: Global Antidepressants Market Forecast (USD billion), by Generalized Anxiety Disorder, 2016-2027

Figure 13: Global Antidepressants Market Forecast (USD billion), by Panic Disorder, 2016-2027

Figure 14: Global Antidepressants Market Forecast (USD billion), by Others, 2016-2027

Figure 15: Global Antidepressants Market Value Share (%), by Distribution Channel, 2019 & 2027

Figure 16: Global Antidepressants Market Forecast (USD billion), by Hospital Pharmacy, 2016-2027

Figure 17: Global Antidepressants Market Forecast (USD billion), by Retail Pharmacy, 2016-2027

Figure 18: Global Antidepressants Market Forecast (USD billion), by Online Pharmacy, 2016-2027

Figure 19: Global Antidepressants Market Value (USD billion), by Region, 2019 & 2027

Figure 20: North America Antidepressants Market Value (USD billion), by Drug Class, 2019 & 2027

Figure 21: North America Antidepressants Market Value Share (%), by Drug Class, 2019

Figure 22: North America Antidepressants Market Value (USD billion), by Disorder, 2019 & 2027

Figure 23: North America Antidepressants Market Value Share (%), by Disorder, 2019

Figure 24: North America Antidepressants Market Value (USD billion), by Distribution Channel, 2019 & 2027

Figure 25: North America Antidepressants Market Value Share (%), by Distribution Channel, 2019

Figure 26: North America Antidepressants Market Value (USD billion), By Country, 2019 & 2027

Figure 27: North America Antidepressants Market Value Share (%), By Country, 2019

Figure 28: Europe Antidepressants Market Value (USD billion), by Drug Class, 2019 & 2027

Figure 29: Europe Antidepressants Market Value Share (%), by Drug Class, 2019

Figure 30: Europe Antidepressants Market Value (USD billion), by Disorder, 2019 & 2027

Figure 31: Europe Antidepressants Market Value Share (%), by Disorder, 2019

Figure 32: Europe Antidepressants Market Value (USD billion), by Distribution Channel, 2019 & 2027

Figure 33: Europe Antidepressants Market Value Share (%), by Distribution Channel, 2019

Figure 34: Europe Antidepressants Market Value (USD billion), By Country/ Sub-region, 2019 & 2027

Figure 35: Europe Antidepressants Market Value Share (%), By Country/ Sub-region, 2019

Figure 36: Asia Pacific Antidepressants Market Value (USD billion), by Drug Class, 2019 & 2027

Figure 37: Asia Pacific Antidepressants Market Value Share (%), by Drug Class, 2019

Figure 38: Asia Pacific Antidepressants Market Value (USD billion), by Disorder, 2019 & 2027

Figure 39: Asia Pacific Antidepressants Market Value Share (%), by Disorder, 2019

Figure 40: Asia Pacific Antidepressants Market Value (USD billion), by Distribution Channel, 2019 & 2027

Figure 41: Asia Pacific Antidepressants Market Value Share (%), by Distribution Channel, 2019

Figure 42: Asia Pacific Antidepressants Market Value (USD billion), By Country/ Sub-region, 2019 & 2027

Figure 43: Asia Pacific Antidepressants Market Value Share (%), By Country/ Sub-region, 2019

Figure 44: Latin America Antidepressants Market Value (USD billion), by Drug Class, 2019 & 2027

Figure 45: Latin America Antidepressants Market Value Share (%), by Drug Class, 2019

Figure 46: Latin America Antidepressants Market Value (USD billion), by Disorder, 2019 & 2027

Figure 47: Latin America Antidepressants Market Value Share (%), by Disorder, 2019

Figure 48: Latin America Antidepressants Market Value (USD billion), by Distribution Channel, 2019 & 2027

Figure 49: Latin America Antidepressants Market Value Share (%), by Distribution Channel, 2019

Figure 50: Latin America Antidepressants Market Value (USD billion), By Country/ Sub-region, 2019 & 2027

Figure 51: Latin America Antidepressants Market Value Share (%), By Country/ Sub-region, 2019

Figure 52: Middle East & Africa Antidepressants Market Value (USD billion), by Drug Class, 2019 & 2027

Figure 53: Middle East & Africa Antidepressants Market Value Share (%), by Drug Class, 2019

Figure 54: Middle East & Africa Antidepressants Market Value (USD billion), by Disorder, 2019 & 2027

Figure 55: Middle East & Africa Antidepressants Market Value Share (%), by Disorder, 2019

Figure 56: Middle East & Africa Antidepressants Market Value (USD billion), by Distribution Channel, 2019 & 2027

Figure 57: Middle East & Africa Antidepressants Market Value Share (%), by Distribution Channel, 2019

Figure 58: Middle East & Africa Antidepressants Market Value (USD billion), By Country/ Sub-region, 2019 & 2027

Figure 59: Middle East & Africa Antidepressants Market Value Share (%), By Country/ Sub-region, 2019

Figure 60: Global Antidepressants Market Share (%), By Company, 2019

List of Tables

Table 1: Global Antidepressants Market Revenue (USD billion) Forecast, by Drug Class, 2016–2027

Table 2: Global Antidepressants Market Revenue (USD billion) Forecast, by Disorder, 2016–2027

Table 3: Global Antidepressants Market Revenue (USD billion) Forecast, by Distribution Channel, 2016–2027

Table 4: Global Antidepressants Market Revenue (USD billion) Forecast, by Region, 2016-2027

Table 5: North America Antidepressants Market Revenue (USD billion) Forecast, by Drug Class, 2016-2027

Table 6: North America Antidepressants Market Revenue (USD billion) Forecast, by Disorder, 2016-2027

Table 7: North America Antidepressants Market Revenue (USD billion) Forecast, by Distribution Channel, 2016-2027

Table 8: North America Antidepressants Market Revenue (USD billion) Forecast, By Country, 2016-2027

Table 9: Europe Antidepressants Market Revenue (USD billion) Forecast, by Drug Class, 2016-2027

Table 10: Europe Antidepressants Market Revenue (USD billion) Forecast, by Disorder, 2016-2027

Table 11: Europe Antidepressants Market Revenue (USD billion) Forecast, by Distribution Channel, 2016-2027

Table 12: Europe Antidepressants Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2016-2027

Table 13: Asia Pacific Antidepressants Market Revenue (USD billion) Forecast, by Drug Class, 2016-2027

Table 14: Asia Pacific Antidepressants Market Revenue (USD billion) Forecast, by Disorder, 2016-2027

Table 15: Asia Pacific Antidepressants Market Revenue (USD billion) Forecast, by Distribution Channel, 2016-2027

Table 16: Asia Pacific Antidepressants Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2016-2027

Table 17: Latin America Antidepressants Market Revenue (USD billion) Forecast, by Drug Class, 2016-2027

Table 18: Latin America Antidepressants Market Revenue (USD billion) Forecast, by Disorder, 2016-2027

Table 19: Latin America Antidepressants Market Revenue (USD billion) Forecast, by Distribution Channel, 2016-2027

Table 20: Latin America Antidepressants Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2016-2027

Table 21: Middle East & Africa Antidepressants Market Revenue (USD billion) Forecast, by Drug Class, 2016-2027

Table 22: Middle East & Africa Antidepressants Market Revenue (USD billion) Forecast, by Disorder, 2016-2027

Table 23: Middle East & Africa Antidepressants Market Revenue (USD billion) Forecast, by Distribution Channel, 2016-2027

Table 24: Middle East & Africa Antidepressants Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2016-2027

REPORT UPDATE
IN PROCESS
STUDY PERIOD: 2019-2032
(In Process)
BASE YEAR:2023
(In Process)

Consulting Services

Healthcare Clients

Related Reports

Get in Touch with Us

US +1 833 909 2966 ( Toll Free )

UK +44 808 502 0280 ( Toll Free )

+91 744 740 1245 (APAC)
[email protected]